Biomea Fusion publishes presentation on BMF-650 Phase 1 obesity study
BMEA•Biomea Fusion published Phase 1 results for its oral obesity drug BMF-650. Outpatients on a 300 mg daily target dose lost 3.2% of baseline weight by day 29, versus 0.1% with placebo.




